UPDATE 2-Alnylam’s rare genetic disorder drug priced at $575,000 per year
Alnylam Pharmaceuticals Inc
priced its gene silencing drug to treat patients with a rare
genetic disorder that can cause severe pain at $575,000 per year
after receiving an early U.S. approval on Wednesday.
priced its gene silencing drug to treat patients with a rare
genetic disorder that can cause severe pain at $575,000 per year
after receiving an early U.S. approval on Wednesday.
Posted by Reuters
